Literature DB >> 18287133

Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.

Alexander W Hauswirth1, Cathrin Skrabs, Christian Schützinger, Markus Raderer, Andreas Chott, Peter Valent, Klaus Lechner, Ulrich Jäger.   

Abstract

Autoimmune thrombocytopenia is a common immunehematologic complication in non-Hodgkin's lymphomas and may complicate the treatment. We analyzed an original series from our institute as well as published cases of non-Hodgkin's lymphomas (excluding chronic lymphocytic leukemia) associated with autoimmune thrombocytopenia with regard to demographic factors, prevalence in non-Hodgkin's lymphoma subtypes and treatment outcome. The male/female ratio is 1.75. Half of the cases occurred prior to diagnosis of lymphoma. Chemotherapy is the best treatment in many non-Hodgkin's lymphomas patients with autoimmune thrombocytopenia compared with standard treatment of autoimmune thrombocytopenia. Splenectomy is effective in splenic marginal zone lymphoma. Autoimmune thrombocytopenia in patients with non-Hodgkin's lymphomas is potentially life-threatening and difficult to treat.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287133     DOI: 10.3324/haematol.11934

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

Review 1.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

2.  A Case of Primary Bone Marrow B-Cell Non Hodgkin's Lymphoma with Severe Thrombocytopenia: Case Report and A Review of the Literature.

Authors:  Yuki Kagoya; Naohi Sahara; Takashi Matsunaga; Toshimasa Uekusa; Seiji Irie; Kazuhito Hatanaka
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-06       Impact factor: 0.900

3.  Multiple cystic lung lesions and autoimmune thrombocytopaenia developing after chemotherapy for pulmonary indolent B-cell lymphoma with plasmacytic differentiation.

Authors:  Hiroaki Tanaka; Chihiro Kuwabara; Yusuke Isshiki; Yoshio Suzuki
Journal:  BMJ Case Rep       Date:  2018-12-13

4.  Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Authors:  Nizar M Tannir; Andres Forero-Torres; Radhakrishnan Ramchandren; Sumanta K Pal; Stephen M Ansell; Jeffrey R Infante; Sven de Vos; Paul A Hamlin; Stella K Kim; Nancy C Whiting; Elaina M Gartner; Baiteng Zhao; John A Thompson
Journal:  Invest New Drugs       Date:  2014-08-22       Impact factor: 3.850

5.  Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination.

Authors:  Saori Harada; Sho Yamazaki; Fumihiko Nakamura; Ken Morita; Akihide Yoshimi; Aya Shinozaki-Ushiku; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

6.  IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia.

Authors:  Kumi Nakazaki; Akira Hangaishi; Fumihiko Nakamura; Masataka Hosoi; Yoichi Imai; Tsuyoshi Takahashi; Yasuhito Nannya; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-07-24       Impact factor: 2.490

7.  Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.

Authors:  Regan H Royer; Jill Koshiol; Therese R Giambarresi; Linda G Vasquez; Ruth M Pfeiffer; Mary L McMaster
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

8.  Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.

Authors:  Kazuyo Nagashima; Hiroaki Tanaka; Yurie Nagai; Yasumasa Sugita
Journal:  BMJ Case Rep       Date:  2016-09-20

Review 9.  Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review.

Authors:  Yuya Kurihara; Kazuki Taoka; Eri Takagi; Kazuhiro Toyama; Kumi Nakazaki; Mineo Kurokawa
Journal:  Intern Med       Date:  2021-05-15       Impact factor: 1.271

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.